LTR Pharma secures Indian patent until 2041
Key points
- The Indian Patent Office granted Patent No. 605429 to LTR Pharma for erectile dysfunction treatment formulations.
- Protection covers intranasal technology for the SPONTAN and ROXUS product lines across the Indian market through May 2041.
- The company plans to use this patent foundation to advance international intellectual property protection and global clinical development programmes.
LTR Pharma (ASX:LTP) secured Indian Patent No. 605429 for its intranasal formulation technology covering erectile dysfunction treatments through May 2041.
This new intellectual property grant adds statutory market protection in India, where previous coverage did not exist.
“The grant of this patent in India is a positive milestone for LTR Pharma, further strengthening the intellectual property portfolio supporting SPONTAN and ROXUS,” said LTR Pharma Executive Chairman Lee Rodne.
The legal protection specifically covers defined formulation characteristics for the company's intranasal delivery systems, subject to ongoing statutory maintenance requirements.
Following the announcement, the LTR Pharma share price was unchanged at $0.45.
The business is developing SPONTAN and ROXUS as fast-acting treatments designed to improve delivery speed compared to oral alternatives.
Management continues to pursue registration and patent rights across key global jurisdictions to support its commercialisation roadmap.
